Diagnos $ADK #DGNOF Signs Memorandum of Understanding with #Essilor International

Diagnos Inc. (“DIAGNOS” or the “Company”) (TSX Venture: ADK) (OTCQB: DGNOF) (FRA: 4D4A), a leader in early detection of critical health issues, is pleased to announce that it has entered into a Memorandum of Understanding (MoU) with the Instruments division of Essilor International, a subsidiary of EssilorLuxottica. Essilor International is the world’s leading ophthalmic optics company. Essilor designs, manufactures and markets a wide range of lenses and diagnostic ophthalmic instruments.

 The MoU is non-binding and forms the basis of a potential distribution agreement with Essilor International for DIAGNOS’ CARA platform for the AI-enhanced analysis of wide-field retinal images, as well as of certain specified future developments of the CARA platform for a variety of applications.

 DIAGNOS has under development multiple new applications involving AI-enhanced retinal imaging to address a growing need for general purpose pathology identification. In addition to localized retinal pathology, such as macular degeneration and glaucoma, certain retinal pathologies are also known indicators of various systemic disorders, including cardiovascular and diabetic diseases. On July 20th 2021, DIAGNOS announced a clinical trial with CommonSpirit Health Research Institute in the USA for the early detection of stroke through the inspection and analysis of the retina.

 “DIAGNOS is focused on its commercialization strategy and pursuing opportunities with potential partners. We are very pleased that our AI-based technology has attracted the attention of global eyecare sector leaders such as Essilor International and we are looking forward to our discussions with respect to a mutually beneficial potential worldwide distribution agreement. At the same time, DIAGNOS continues to invest in Research and Development, furthering the creation of our intellectual property by partnering with Quebec government programs and local university (École de Technologie Supérieure) to ensure that we stay ahead of our competition worldwide,” said Mr. André Larente, President of DIAGNOS

Diagnos $ADK $DGNOF Initiates a Clinical Trial Study in the USA for Early Detection and Prevention of Stroke Using it new Application CARA-STROKE

Diagnos Inc. (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues, announces today the initiation of a clinical trial study with CommonSpirit Health Research Institute, Chattanooga Center for Neurologic Research LLC and conducted at the CommonSpirit Hospital in Chattanooga, to confirm early Proof-of-Concept results that showed a strong potential in the early detection of stroke through the inspection and analysis of the retina.

The clinical trial will be carried out under the direction of Thomas G Devlin M.D., PhD. The IRB study has been approved by an Institutional Review Board (“IRB”) in compliance with all applicable regulations in the USA.

“DIAGNOS will be providing the necessary hardware and technical support during the first phase of the clinical trial. DIAGNOS will have access to all the results tests performed on patients who are admitted to the hospital following a stroke and who meet the study’s inclusion criteria. The tests performed on these patients will include taking images of the retina using DIAGNOS’ CARA-ST technology. The analysis of the retina by our AI application will be done immediately and all medical staff in the clinical trial will have access to it through our FDA-approved Tele-Medicine platform. The initial goal of the first phase of the study is to demonstrate that the results using CARA-ST correlate with the results of the other clinical results. If successful, the second phase would start shortly thereafter and will be screening over 1,000 patients at the same facility and also a new facility in Canada.

DIAGNOS is seeking to demonstrate that CARA-ST will be able to predict the early signs of the condition leading to stroke, based on the micro circulation analysis of the retina image of the patient.

As per CDC-The Center for Disease Control and Prevention, stroke causes 1 out of every 20 deaths, the management of stroke represents a cost of around USD 34 billion per year in the United States. Hence, early diagnosis and treatment to prevent deaths from stroke is a time sensitive necessity.

According to the World Health Organization, 15 million people suffer a stroke worldwide each year. Of these, 5 million die and another 5 million are permanently disabled. High blood pressure contributes to more than 85% of strokes worldwideEurope averages approximately 650,000 stroke related deaths each year.

“According to new reports published by Worldwide Research Institutes, the worldwide market size for Stroke Management will hit over $66 Billion dollars by 2023. DIAGNOS intends to be part of the solution by making available an affordable predictive test to the general public’’ said Mr. André Larente, President of DIAGNOS.

“At DIAGNOS we have continued to invest in Research and Development, furthering the creation of our intellectual property by partnering with Quebec government programs and local university (École de Technologie Supérieure) to ensure we stay ahead of our competition worldwide. This year our new stroke management application will be field tested in multiple countries. For our investors this ground-breaking test comes at an ideal time in terms of shareholder value creation as the combination of both CARA-DR and CARA-ST tools will be transformational in helping to monitor the health of existing and future patients with cardiovascular disease,” said Mr. Andre Larente, President of DIAGNOS.

About CommonSpirit

CommonSpirit Health is a non for profit, Catholic health system dedicated to advancing health for all people. It was created in February 2019 through the alignment of Catholic Health initiatives and Dignity Health. With a team of approximately 125,000 physicians and advanced practice clinicians. CommonSpirit Health operates 137 hospitals and more than 1,000 care sites across 21 states. In FY2020, Catholic Health initiatives and Dignity Health had combined revenues of nearly $29.6 billion and provided $4.6 billion in charity care, community benefit and unreimbursed government programs.

Diagnos $ADK Announces a Pilot with Hospital Oftalmologico Buena Vista Sinaloa

Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF) (FRA: 4D4A), BROSSARD, Quebec, June 09, 2021 (GLOBE NEWSWIRE) — Diagnos Inc. (“DIAGNOS” or the “Company”) (TSX Venture: ADK) (OTCQB: DGNOF) (FRA: 4D4A), a leader in early detection of critical health issues, announces today the signing of a 2-month pilot with Hospital Oftalmológico Buena Vista Sinaloa, the largest ophthalmological hospital in Sinaloa State, Mexico.

In Mexico there are 18 million diabetics with a 23% prevalence in people of 20 years or more; the seriousness of these cases is that every hour in the country eight patients die from this disease, since 80% of deaths in Mexico, is related to diabetes. In Sinaloa State, 355,000 thousand cases are reported, of which almost half (175,000) are undiagnosed, with a prevalence of 21% of the population of 20 years or more. Of the 180,000 diagnosed for diabetes, only 30% go to the doctor on a regular basis. According to statistics, 30,000 new cases of diabetes per year are registered in the State of Sinaloa. Diabetic Retinopathy and loss of vision are the 2 biggest problems.

“For almost 25 years, we’ve been providing ophthalmic eye care to hundreds of thousands of patients coming from 4 out of 9 States of the Northern Region of Mexico, mainly the west pacific area. Our focus is to provide our specialty services to everybody within one of our 7 eye health programs such as Ophthalmological Consultation, Surgeries, Culture of Prevention of Eye Diseases, Campaign of Free Consultation in Suburban Areas to People in Extreme Poverty, National Museum of Ophthalmology, among others”, mentions Dr. Efraín Romo Santos, Founder and Head of Ophthalmology at Hospital Oftalmológico Buena Vista Sinaloa. “We’re excited to welcome DIAGNOS as we look forward to use a real-life tested technology based on AI, reliable and compliant with the most exigent international standards”, finished Dr. Romo.

“This is a great moment for DIAGNOS as we’ve been proving that our AI and Telemedicine modules helps safety issues around specialists and their staff during this challenging time. We will be demonstrating our service of retina screening to everyone that needs it”, says Mr. Guillermo Moreno, Vice President of DIAGNOS. “Along with Dr. Romo, we’ll provide a turn-key solution to his renowned team of specialists, we’re confident that during the pilot, we’ll deliver a real-time result to the local population by supporting the specialists in their day to day. Finally, we will give hope to patients through the access to eye screening with Dr. Romo’s Institutions”, finished Mr. Moreno.

About Hospital Oftalmológico Buena Vista Sinaloa

At Buena Vista Sinaloa we have been dedicated for more than 24 years to providing efficient ophthalmic treatments for the diagnosis and prevention of eye diseases to each of our clients in Culiacán (HD), Los Mochis and Mazatlan, all three in Sinaloa State, Mexico.

Buena Vista Sinaloa began activities on December 6, 1996, its founder Dr. Efraín Romo Santos, has managed to form an institution with doctors and specialists in ophthalmology, as well as with cutting-edge equipment to care for patients in different states such as Sinaloa, Durango, Baja California Sur and Sonora.

About DIAGNOS:

DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its FLAIRE Artificial Intelligence (AI) platform.  FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients. CARA has been cleared for commercialization by the following regulators: Health Canada, the FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia).

Additional information is available at www.diagnos.com and www.sedar.com

For further information, please contact:

Mr. André Larente, President

DIAGNOS Inc.

Tel: +1-450-678-8882 ext. 224

Email: alarente@diagnos.ca

#Renforth #Resources $RFR Completes New Alger #Purchase

#RenforthResources $RFR has completed the New Alger #joint #venture, resulting in Renforth assuming 100% ownership of the New Alger mining concession, subject to a 2% NSR.

New Alger hosts an inferred gold resource of 237,000 ozs of gold located above a depth of 200m in the area of the former Thompson-Cadillac mine. The Thompson-Cadillac mine saw small-scale operation prior to the Second World War, resulting in the production of 21,000 ozs of gold at an average grade of 4.2 g/t Au.

Renforth_logo_final“We are happy to have attained complete ownership of New Alger. Renforth has had a long relationship with this property, successfully putting in place the first resource statement and rediscovering the gold system in the sediments. Management looks forward to, funding permitting, being able to continue to define how much gold is contained in this 1.4-kilometre portion of the Cadillac Break and in the Pontiac sediments to the south with future exploration programs,” states Nicole Brewster, president and chief executive officer of Renforth.

#Metanor $MTO $MEAOF Confirms the Extension of the #Gold Structure at Depth on the #Moroy #Property

White Logo

Metanor Resources Inc. (“Metanor”) (TSX VENTURE:MTO) (OTCBB:MEAOF) is pleased to announce the drilling results for the new zone on the Moroy property located 1 km from the Bachelor mill.

The drilling from the last few weeks allowed to define the extension of the gold structure from surface down to 650 m deep; the structure was intercepted by drill holes at depth of 50, 100, 400, 600, and 650 meters, see section below.

These first 3,800 meters of the drill campaign also allowed the confirmation of a sub-vertical structure ranging between 1 and 5 meters. Moreover, the drill campaign in 2015 confirmed the presence of a gold structure 570 m long east to west.

Hole From (m) To (m) Length (i) Grade (g/t Au) (ii)
MO-16-103b 332 332.9 0.8 2.1
MO-16-103b 429.4 429.8 0.4 3.4
MO-16-103b 527.1 527.4 0.3 12.6
MO-16-103b 544.3 545.9 1.6 6.9
MO-16-103b 554 556.4 2.4 2.5
MO-16-106 44.6 47.5 2.9 2.6
MO-16-107 29.6 33 3.4 3.7
MO-16-108 39.4 42.7 3.3 1.2
MO-16-114 25.5 27.1 1.6 5.3
MO-16-116 103.7 106.8 3.1 2.8
MO-16-117 35.6 37.8 2.2 6.9
MO-16-119 85.3 87.6 2.2 0.2
MO-16-121 71.3 72.9 1.6 0.6
MO-16-122 32.1 33.6 1.5 2.4
MO-16-124 17 19 2.1 3.8
MO-16-130 606.9 608 1.1 2.7
MO-16-131 444.5 447 2.5 5.5
MO-16-133 10.7 12 1.3 9.1
MO-16-135 8.3 14.8 6.6 3.8
including 9.1 10.6 1.5 12.2
MO-16-136 30.5 31.3 0.8 5.2
MO-16-138 28 28.3 0.3 2.8
MO-16-139 8.3 14.8 6.6 1.8
including 9.1 10.6 1.5 9.2
MO-16-139 73.6 75.1 1.5 2
MO-16-140 84 87.4 3.4 6.7
MO-16-141 117.6 118.1 0.6 2.2
MO-16-141 160.2 160.8 0.6 2.7
MO-16-144 57.8 58.4 0.6 3.7
MO-16-144 79.6 80.5 0.9 5.2
MO-16-144 160.9 161.5 0.6 2.2

*Core length

Meanwhile, the 2016 drilling campaign expected to total 60,000 meters is progressing. A first drill is focusing on the zones near surface, from 0 to 150 m deep, at a drill spacing of 25 m between each hole so mineral resources may be defined at the end of the campaign. A second drill rig will target the same structure at depths ranging between 150 and 300 m and a third drill rig, expected to begin in May, will aim to define the lateral extensions to the east and to the west.

Metanor estimates that the mineralized intercepts’ true thicknesses reach 70 to 95% of the drill cores. A capping of 31 g/t was used or 1 Au ounce. The Company uses a rigorous, industry-standard, QA/QC program. The samples were assayed by fire-assay at the Metanor assay lab. Blanks, duplicates and certified reference standards are inserted into the sample stream to monitor laboratory performance. The quality control program of the assay results (QA/QC) adopted by Metanor includes a minimum of 10% of controlled assays being conducted as well as verification by an independent ALS-certified assay laboratory in Val-d’Or, Québec. Results of the spot checks were consistent with those reported.

Qualified Person

Pascal Hamelin, P. Eng., Vice-president of Operations, is the Qualified Person under NI 43-101, responsible for reviewing and approving the technical information contained in this news release

To view the maps associated with this press release, please visit the following link: Maps for Moroy Property

Metanor $MTO $MEAOF Begins Drilling to Update the #Mineral #Resources of the Barry #Gold #Project #Quebec

Metanor $MTO $MEAOF announced the start of a drilling campaign to update the mineral resources of its Barry Gold Project.

       White Logo

The campaign of 1,200 meters will include validation drilling of the high-grade zones and of the extensions of certain mineralized zones, for eventual open pit mining.

The campaign and the mineral resource update is the first step towards the establishment of a preliminary economic assessment study on the Barry Project. The mineral resources are 7.7 millions of metric tons at a grade of 1.25 g/t for 309,500 ounces of indicated resources, and 10.411 millions of metric tons at 1.41 g/t for 471 950 ounces of inferred resources.

Metanor expects the drilling to be completed in May and the assessment to be completed at the end of June 2016.

Nancy

Metanor $MTO Retains GoldMinds Geoservices for a #Mineral #Resource Update on its Barry #Gold #Project #Quebec

Given the advantageous gold price in Canadian Dollar, Metanor is evaluating the merit of resuming work at the Barry project and has retained GoldMinds Geoservices Inc. to provide a mineral resource update on this gold project.

White LogoThe study will include validation drilling of the high-grade zones and the extensions of certain mineralized zones, for eventual open pit mining.

Nancy

Metanor $MTO Intersects 9.2 g/t #Gold Over 6.4 M at the Moroy Project #Quebec

Metanor Resources (TSX.V-MTO) (OTCBB:MEAOF) started drilling on the Moroy project in late February and has intersected 9.2 g/t gold over 6.4 metres, near surface. A second drill was planned to commence in the following days. This drill campaign is expected to cover over 60,000 m in the area, one km south of the Bachelor Mine.

Metanor expects to use three drills to complete this program, with two drill making close-space drillings to identify a well-defined resource and the third to drill at greater depths, targeting the geological anomalies identified in 2015.

White Logo

Nancy

Metanor $MTO $MEAOF Starts #Drilling the Moroy’s New Anomalies #Quebec

Metanor Resources – TSX.V-MTO OTCBB-MEAOF – has started the surface drill campaign targeting the Moroy’s new anomalies.

White Logo

This new mineralized zone is located 1 km south-east of the Bachelor Mine. The first drill holes are targeting the anomalies located just below the mineralized zones discovered on surface. A second drill is expected to be added in March to accelerate the campaign. The ongoing drill campaign is expected to cover some 60,000 meters on the Moroy property.

www.metanor.ca

Nancy

Metanor $MTO $MEAOF Prepares New Drilling Campaign for the Moroy Zone and Evaluates Resuming Operations at the Barry Open Pit

Metanor announced that it is studying the possibility of restarting gold mining operations at their open pit on its 100% owned Barry property.

Table 1: Summary of Resources, Barry Open Pit (from 2010 NI 43-101 Report by Duplessis & Camus1)

Class

Tonne

Au g/t
uncapped

Au g/t
capped

Ounces Au
(capped)

Indicated

7,701,000

1.29

1.25

309,500

Inferred

10,411,000

1.65

1.41

471,950

Resources above 0.5 g/t, capping 35 g/t on assay

Ghislain Morin, President and Chief Executive Officer of Metanor stated: “We feel that the metrics are optimal for a restart of operations at the Barry Pit. Our surface infrastructure is still operational, and the mining permit is still active. Combining this with the current low fuel prices and a gold value of $1,700 per ounce in Canadian dollars, we see restarting as an attractive option for the Company at this time.”

Metanor is also planning a drill campaign at their Moroy project, located one kilometre southeast of the Bachelor Mine. The company is creating a number of ice bridges to allow drill-rig access and have scheduled drilling to commence before the end of this month.

See full news release dated February 11, 2016 at www.metanor.ca

Nancy